• Dimerix to host live streamed investor webinar on May 1, 2025
• Presentation to cover US licensing transaction for DMX-200 and Phase 3 clinical trial progress
• DMX-200 is Dimerix's proprietary Phase 3 product candidate for Focal Segmental Glomerulosclerosis (FSGS) kidney disease

Dimerix Limited (ASX: DXB), a biopharmaceutical company with a Phase 3 clinical asset, DMX-200, in a rare kidney disease, is pleased to provide an opportunity for shareholders, investors and brokers to join a live streamed presentation on May 1, 2025. The presentation will be delivered by Dimerix CEO & Managing Director, Dr Nina Webster, and will discuss the recent announcement on the US licensing transaction for DMX-200, as well as the ongoing Phase 3 clinical trial progress. DMX-200 is Dimerix's proprietary product candidate for the treatment of Focal Segmental Glomerulosclerosis (FSGS), a rare and serious kidney disorder. The company has received Orphan Drug Designation for DMX-200 in both the US and Europe for FSGS, which provides various development incentives. Dimerix reported positive Phase 2a data for DMX-200 in FSGS patients in July 2020, and is now focused on advancing the Phase 3 clinical development of this promising asset.